Nanobiotix stock breaks through its €19.12 support level with RSI at 22.8

A monthly decline of 37.6% placing the stock below all three moving averages

Nanobiotix falls 2.62% to €18.62 during the session, against the grain of the SBF 120 which loses 1.33% but at the bottom of the index, among the trailing positions. The stock shows a 12.3% decline over one week and 37.6% over one month. The support level at €19.12 has broken, which is accompanied by a price now 23.7% below the 20-day moving average and 35.3% below the 200-day moving average.

The RSI at 22.8 reflects the magnitude of the selling sequence, the same that had already caused the stock to fall nearly 2% on October 13, with an RSI then at 25. This movement extends a series of successive lows: the stock broke its support at €27.94 on September 28, then that at €22.38 on October 7. Over one year, the decline still reaches 16.5%.

Liquidity of €110.9 million financing operations through 2029

The pullback comes as the company published its operational update for the first half of 2026 on September 24. Cash reserves reached €110.9 million, compared to €52.8 million at the end of December 2025, following a capital increase of approximately €86 million completed in May. The company indicates that these liquid assets will enable it to finance its operations through 2029.

Nanobiotix is developing the radioamplifier NBTXR3 (JNJ-1900), associated with radiotherapy, in partnership with Johnson & Johnson. The stock is listed both on Euronext Paris, where it is eligible for the PEA, and on Nasdaq in the form of ADS, at a rate of one ADS per ordinary share. The next technical level to monitor is the €19.12 support, now broken and having become an upper bound for the current price.